Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer

Oncology Reports

Volumn 12, Issue 5, 2004, Pages 1143-1150

  Peters, Maria Giselle ^a,c   Vidal, Maria Del Carmen C ^a   Giménez, Liliana ^b   Mauro, Laura ^a   Armanasco, Eduardo ^a   Cresta, Carlos ^a   Joffé, Elisa Bal De Kier ^a,c   Puricelli, Lydia ^a,c  

^a Institute of Oncology 'Angel H Roffo'   (Argentina)

^b Institute of Oncology 'Angel H Roffo'   (Argentina)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Breast cancer; Cyclin; Cyclin dependent inhibitors; p16; p21; Tumor marker

Indexed keywords

CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN B; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; PROTEIN P16INK4A; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; CELL CYCLE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PROGNOSIS; SURVIVAL RATE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN B; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 16544368153     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.5.1143     Document Type: Article

References (42)

1. Matos E, Loria D, Zengarini N, Fernández MM, Gueveln C, Marconi E, Spitale A and Rosso S: Atlas de mortalidad por cancer en Argentina, 1997-2001. Matos E and Loria D (eds). Buenos Aires, 2003.
2. Spyratos F, Hacene K, Tubiana-Hulin M, Pallu C and Brunet M: Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1262 patients. Eur J Cancer Clin Oncol 8: 1233-1240, 1989.
3. McGuire WL: Steroid receptors in human breast cancer. Cancer Res 38: 4289-4291, 1978.
4. Gullick WJ, Berger MS, Bannett PLP, Rothbard JB and Waterfield MD: Expression of the c erb B2 protein in normal and transformed cells. Int J Cancer 40: 246-254, 1987.
5. Rochefort H: Cathepsin D in breast cancer. Breast Cancer Res Treat 16: 3-13, 1990.
6. Sherr CJ: G1 phase progression: cyclin on cue. Cell 79: 551-555, 1994.
7. Waga S, Hannon GJ, Beach D and Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.
8. Hunter T and Pines J: Cyclins and cancer. Cell 66: 1071-1074, 1991.
9. Wang J, Chenivesse X, Henglein B and Brechot C: Hepatitis B virus integration in a cyclin A gene in hepatocellular carcinoma. Nature 343: 555-557, 1990.
10. Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Musgrove EA and Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene 8: 2127-2133, 1993.
11. Lammie GA, Fantl V, Smith R, Shuuring E, Brooks S, Michalides R, Dickson C, Arnold A and Peters G: D11S287, a putative oncogene on chromosome 11 q 13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6: 439-444, 1991.
12. Bastkova J, Lukas J, Müller H, Lützhoft D, Strauss M and Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57: 353-361, 1994.
13. Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S and Sauter G: Cyclin E overexpression and amplification in human tumors. J Pathol 200: 375-382, 2003.
14. Diab SG, Yu YY, Hilsenbeck SG, Allred DC and Elledge RM: WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res Treat 43: 99-103, 1997.
15. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
16. Sambrook J, Fitsch E and Maniatis T: Molecular cloning: a laboratory manual. Cold Spring Harbor Press, NY, 1989.
17. Parwaresch R and Rudolph P: The cell cycle-theory and applications to cancer. Onkologie 19: 464-472, 1996.
18. Kawamoto H, Koizumi H and Uchikoshi T: Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in non-malignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am J Pathol 150: 15-23, 1997.
19. Sherr JS: Cancer cell cycles. Science 274: 1672-1677, 1996.
20. Lukas J, Bartkova J and Bartek J: Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled Gl checkpoint. Mol Cell Biol 16: 6917-6925, 1996.
21. Russell A, Thompson MA, Hendley J, Trute L, Armes J and Germain D: Cyclin Dl and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene 18: 1983-1991, 1999.
22. Geradts J and Ingram C: Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast. Mod Pathol 13: 945-953, 2000.
23. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R and Peterse J: A clinicopathological study on overexpression of cyclin Dl and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73: 728-734, 1996.
24. Spyratos F, Andrieu C, Vidaud D, Briffod M, Vidaud M, Lidereau R and Bieche I: CCND1 mRNA overexpression is highly related to estrogen receptor positivity but not to proliferative markers in primary breast cancer. Int J Biol Markers 15: 210-214, 2000.
25. Utsumi T, Yoshimura N, Maruta M, Takeuchi S, Ando J, Mizoguchi Y and Harada N: Correlation of cyclin D1 mRNA levels with clinicopathological parameters and clinical outcome in human breast carcinomas. Int J Cancer 89: 39-43, 2000.
26. Gao CY and Zelenka PS: Cyclins, cyclins dependent kinases and differentiation. Bioassays 19: 307-315, 1997.
27. Zwijsen RM, Bucle RS, Hijmans EM, Loomans CJ and Bernards R: Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin Dl. Genes Dev 12: 3488-3498, 1998.
28. Wong S, Chan J, Lee K and Hsiao W: Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. J Pathol 194: 35-42, 2001.
29. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of Gl-phase progression. Genes Dev 13: 1501-1512, 1999.
30. Lodén M, Nielsen NH, Roos G, Emdin SO and Landberg G: Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene 18: 2557-2566, 1999.
31. Sheaff RJ, Groudine M, Gordon M, Roberts JM and Clurman BE: Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 11: 1464-1478, 1997.
32. Strohmaier H, Spruck CH. Kaiser P, Wong KA, Sangfelt O and Reed SI: Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413: 316-322, 2001.
33. Lodén M, Stighall M, Nielsen NH, Roos G, Emdin SO, Ostlund H and Landberg G: The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 21: 4680-4690, 2002.
34. Donnellan R, Kleinschmidt I and Chetty R: Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. Hum Pathol 32: 89-94, 2001.
35. Barbareschi M, Doglioni C, Veronese S, Bonzanini M, Dalla Palma P, Harris AL and Caffo O: p21WAF1 and p53 immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment. Eur J Cancer 32A: 2182-2123, 1996.
36. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K and Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21 (Cip1/WAF1) in monocytic differentiation. EMBO J 18: 1223-1234, 1999.
37. Winters ZE, Hunt NC, Bradburn MJ, Royds JA, Turley H, Harris AL and Norbury CJ: Subcellular localisation of cyclin B, Cdc2 and p21 WAF1/CIP1 in breast cancer: association with prognosis. Eur J Cancer 37: 2405-2415, 2001.
38. Tsihlias J, Kapusta L and Slingerland J: The prognositc significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 50: 401-423, 1999.
39. Dulic V, Stein GH, Far DF and Reed SI: Nuclear accumulation of p21 cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Biol 18: 546-557, 1998.
40. Rudolph P, Kühling H, Alm P, Ferno M, Baldetorp B, Olsson H and Parwaresch R: Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal woman with lymph node-negative breast cancer. Int J Cancer 105: 674-680, 2003.
41. Megha T, Lazzi S, Ferrari F, Vatti R, Howard CM, Cevenini G, Leoncini L, Luzi P, Giordano A and Tosi P: Expression of the G2-M checkpoint regulators cyclin B1 and p34 cdc2 in breast cancer: a correlation with cellular kinetics. Anticancer Res 19: 163-169, 1999.
42. Bowe DB, Kenny NJ, Adareth Y and Maroulakou IG: Suppression of Neu-induced mammary tumor growth in cyclin Dl deficient mice is compensated for by cyclin E. Oncogene 21: 291-298, 2001.